「PHARMACOLOGICAL ACTION」に関連した英語例文の一覧と使い方(2ページ目) - Weblio英語例文検索

The deodorized Actinidia polygama having good flavor is obtained by extracting Actinidia polygama or the foliage of Actinidia polygama with an organic acid or an organic acid-containing liquid at 10-80°C, by selectively decreasing ingredients such as actinidine and matatabilactone while effectively retaining ingredients, etc., having nourishing/nutritional ingredients and pharmacological action which Actinidia polygama contains to remove the undesirable odor of Actinidia polygama.例文帳に追加

マタタビ或いはマタタビの茎葉を、１０〜８０℃の温度条件下、有機酸又は有機酸含有液体で抽出処理することにより、マタタビの含有する滋養・栄養成分や薬理作用を有する成分等を有効に保持しながら、アクチニジンやマタタビラクトン等の成分を選択的に減少させ、マタタビの好ましくない臭いを除去し、香味の良い除臭マタタビを得る。 - 特許庁

The pharmacological composition or the composition for foods and drinks for neutralizing toxicity of a toxin causative of food poisoning (provided that extracellular toxins of enterohemorrhagic Escherichia coli are excluded) comprising extracts from snakes exhibits "an action for neutralizing a toxin" strongly even in a very small amount against a toxin causative of food poisoning (provided that extracellular toxins of enterohemorrhagic Escherichia coli are excluded).例文帳に追加

ヘビ抽出物を含有する、食中毒原因毒素（ただし、腸管出血性大腸菌の菌体外毒素を除く）の毒性を中和するための薬学的組成物、飲食用組成物により、食中毒原因毒素（ただし、腸管出血性大腸菌の菌体外毒素を除く）に対してごく少量でも強く「毒素を中和する作用」を発揮する薬学的組成物や飲食用組成物が提供される。 - 特許庁

To provide a hydrolysate which is separated from fruiting body or mycelium of kinji (fungi belonging to Tremellaceae) and which shows the similar pharmacological action to high molecular weight acidic heteropolysaccharides which are insoluble in organic solvents and soluble in water and which is far less viscous than the high molecular weight acidic heteropolysaccharides and which can be conveniently used, a medicine containing this as an active ingredient and food and drink containing this.例文帳に追加

金耳の子実体若しくは菌子体から分離される、有機溶媒に不溶で、水に可溶の高分子量酸性ヘテロ多糖と同様の薬理作用を有し、しかも該高分子量酸性ヘテロ多糖よりもはるかに低粘性で、したがってその使用に都合の良い加水分解物、これを有効成分とする薬剤及びこれを含有する飲食品を提供する。 - 特許庁

(1) Studies of receptor/target binding affinity and occupancy, using target human cells or cells from appropriate animal species (2) Dose-response curves in target human cells or cells from appropriate animal species (3) Estimated exposure in humans at pharmacological doses in appropriate animal species. In order to avoid the potential for adverse reactions in humans, a safety factor may be applied in the calculation of the first-in-human dose from the MABEL. This should take into account risk factors such as the novelty, bioactivity, and mode of action of the investigational product, the degree of species specificity, the shape of the dose-response curve, and the degree of uncertainty in the calculation of the MABEL. The appropriate safety factors should be set.例文帳に追加

① ヒト及び適切な動物種由来の標的細胞を用いた受容体／標的への結合親和性及び占有率についての試験 ② ヒト及び適切な動物種由来の標的細胞を用いた用量－反応曲線 ③ 適切な動物種を用いた薬理学的用量における推定曝露量ヒトにおける有害作用の発現を回避するために，安全係数を適用して，MABELから初回投与量を設定する場合には，被験薬の新規性，生物学的活性，作用機序，被験薬の種特異性，用量作用曲線の型等を踏まえ，適切な安全係数を設定すべきである． - 厚生労働省